Neurotoxicity and neuroprotection in the DBA/2J spontaneous model of glaucoma
DBA/2J 自发性青光眼模型的神经毒性和神经保护
基本信息
- 批准号:8237645
- 负责人:
- 金额:$ 48.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-12-01 至 2015-11-30
- 项目状态:已结题
- 来源:
- 关键词:ApoptosisApoptoticBackcrossingsBindingBinding ProteinsBlindnessBrainCD95 AntigensCell DeathCell Surface ProteinsCellsCessation of lifeChronic DiseaseCleaved cellClinicalCoculture TechniquesDevelopmentDiseaseDisease ProgressionEyeGlaucomaImmuneIn VitroInflammatory InfiltrateKnock-in MouseLeadMediatingMediator of activation proteinMembraneMetalloproteasesMicrogliaModelingMolecularMouse StrainsMusMutateMutationNeurogliaPathogenesisPatientsPhysiologic Intraocular PressurePredispositionPrimary Open Angle GlaucomaProblem SolvingResearchRetinaRetinalRetinal Ganglion CellsScientistSiteSystemTestingTherapeutic InterventionTimeTissuesTumor Necrosis Factor Ligand Superfamily Member 6Workbasecell typein vivointerestneuroprotectionneurotoxicneurotoxicitynovelpressurepreventpro-apoptotic proteinresponse to injuryretinal apoptosisretinal neuronstem
项目摘要
DESCRIPTION (provided by applicant): Glaucoma is one of the most common causes of blindness worldwide and, while there are many different forms of glaucoma that differ significantly in clinical presentation and disease progression, they all share a common endpoint which is the loss of retinal ganglion cells (RGCs). New treatments are needed, since current therapies can delay, but not stop disease progression. One of the major barriers to the development of novel treatments is the incomplete understanding of the disease pathogenesis. Recent evidence indicates the loss of RGCs is due to apoptosis, nevertheless, the actual molecular mechanism that triggers apoptosis is still controversial. Fas Ligand (FasL) is a pro-apoptotic protein that is constitutively expressed in the retina where it is thought to protect tissue from destruction by maintaining immune privilege, either by inducing apoptosis of infiltrating inflammatory cells or by preventing neoangeogenesis. However, there are two forms of FasL, a membrane-bound form (mFasL) and a soluble form (sFasL) that is produced by metalloproteinase cleavage of the membrane-bound protein. Our previous studies on the function of mFasL and sFasL indicate that mFasL is pro-apoptotic, while sFasL is anti-apoptotic. We recently developed a unique knock-in mouse strain in which the FasL metalloproteinase cleavage sites were mutated to prevent cleavage of the membrane-bound protein. In these mice, FasL is expressed and regulated normally, but they are unable to cleave FasL and therefore, can only express mFasL (termed ? CS mice). For the first time, these mice have allowed us to study the in vivo function of membrane FasL in the absence of soluble FasL. In order to determine the function of mFasL in the development of glaucoma, we backcrossed the ? CS knock-in mutation into the DBA/2J strain (D2. ? CS mice) that develops spontaneous elevated intraocular pressure (IOP) and loss of RGCs. Our preliminary results indicate that mFasL is a critical mediator of RGC apoptosis during the development of glaucoma. Moreover, sFasL has an important neuroprotective effect that not only prevents loss of RGCs, but also protects other retinal neurons in hypertensive eyes. We hypothesize that in response to injury caused by elevated IOP, there is increased expression of Fas and FasL within the retina. However, the extent of retinal apoptosis is determined by the ratio of membrane / soluble FasL expressed by microglia. Neurotoxic microglia express higher levels of mFasL, while neuroprotective microglia express higher levels of sFasL. This hypothesis will be tested in three Specific Aims: (Aim 1) Demonstrate that elevated IOP in D2. ? CS mice that are unable to cleave FasL triggers increased retinal neurotoxicity. (Aim 2) Determine whether increased retinal neurotoxicity in D2. ? CS mice is due to increased mFasL expression and/or the absence of sFasL. (Aim 3) Determine the mechanisms of microglia-mediated neurotoxicity in vitro using a co-culture system with immortalized retinal microglia from D2. ? CS mice and primary RGCs.
PUBLIC HEALTH RELEVANCE: Glaucoma is a chronic disease that can ultimately lead to loss of vision and blindness. The loss of vision occurs when a certain type of cell in your retina dies (retinal ganglion cells). It is unclear to scientists exactly why these cells die. We have discovered at least one reason why these cell die. In addition, we have also found a way to stop these cells from dying. This research will lead to novel targets for therapeutic intervention in glaucoma.
描述(申请人提供):青光眼是全球最常见的致盲原因之一,尽管有许多不同形式的青光眼在临床表现和疾病进展方面存在显著差异,但它们都有一个共同的终点,即视网膜神经节细胞(RGC)的丧失。需要新的治疗方法,因为目前的治疗方法可以延缓但不能阻止疾病的进展。开发新的治疗方法的主要障碍之一是对疾病发病机制的不完全了解。近年来的研究表明,视网膜节细胞的丢失与细胞的凋亡有关,然而,细胞凋亡的分子机制仍存在争议。Fas配体(Fas Ligand,FasL)是一种在视网膜中结构性表达的促凋亡蛋白,通过诱导浸润性炎症细胞的凋亡或防止新生血管生成,它被认为通过维持免疫豁免权来保护组织免受破坏。然而,有两种形式的FasL,一种是膜结合型(MFasL),另一种是由膜结合蛋白的金属蛋白酶裂解产生的可溶型(SFasL)。我们前期对mFasL和sFasL功能的研究表明,mFasL具有促凋亡作用,而sFasL具有抗凋亡作用。我们最近开发了一种独特的敲入小鼠品系,其中FasL金属蛋白酶裂解位点发生突变,以防止膜结合蛋白的裂解。在这些小鼠中,FasL正常表达和调节,但它们不能切割FasL,因此只能表达mFasL(称为?CS小鼠)。这些小鼠第一次允许我们在没有可溶性FasL的情况下研究膜FasL的体内功能。为了确定mFasL在青光眼发生发展中的作用,我们回交了?CS敲入突变株DBA/2J(D2.?出现自发性高眼压和视网膜节细胞丢失。我们的初步结果表明,在青光眼的发展过程中,mFasL是RGC细胞凋亡的关键介质。此外,sFasL具有重要的神经保护作用,不仅可以防止RGC的丢失,还可以保护高血压眼的其他视网膜神经元。我们推测,作为对高眼压引起的损伤的反应,视网膜内存在Fas和FasL的表达增加。而小胶质细胞表达的膜/可溶性FasL的比值决定了视网膜细胞的凋亡程度。神经毒性小胶质细胞表达较高水平的mFasL,而神经保护性小胶质细胞表达较高水平的sFasL。这一假设将在三个具体目标中得到验证:(目标1)证明D2眼压升高。?不能切割FasL的CS小鼠会触发视网膜神经毒性增加。(目的2)确定D2期视网膜神经毒性是否增加。?CS小鼠是由于mFasL表达增加和/或sFasL缺失所致。(目的3)利用D2永生化的视网膜小胶质细胞共培养体系,体外研究小胶质细胞介导的神经毒性机制。?CS小鼠和原代视网膜神经节细胞。
与公共卫生相关:青光眼是一种慢性疾病,最终会导致失明和失明。当视网膜中的某种细胞(视网膜神经节细胞)死亡时,就会发生视力丧失。科学家们还不清楚这些细胞死亡的确切原因。我们已经发现了这些细胞死亡的至少一个原因。此外,我们还找到了阻止这些细胞死亡的方法。这项研究将为青光眼的治疗干预带来新的靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MEREDITH GREGORY-KSANDER其他文献
MEREDITH GREGORY-KSANDER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MEREDITH GREGORY-KSANDER', 18)}}的其他基金
Fas Ligand Cleavage regulates ocular homeostasis and glaucoma
Fas 配体裂解调节眼稳态和青光眼
- 批准号:
10374484 - 财政年份:2022
- 资助金额:
$ 48.5万 - 项目类别:
Fas Ligand Cleavage regulates ocular homeostasis and glaucoma
Fas 配体裂解调节眼稳态和青光眼
- 批准号:
10867990 - 财政年份:2022
- 资助金额:
$ 48.5万 - 项目类别:
Fas Ligand Cleavage regulates ocular homeostasis and glaucoma
Fas 配体裂解调节眼稳态和青光眼
- 批准号:
10550147 - 财政年份:2022
- 资助金额:
$ 48.5万 - 项目类别:
Regulation of the neuroinflammatory response in autoimmune uveitis
自身免疫性葡萄膜炎神经炎症反应的调节
- 批准号:
10320063 - 财政年份:2021
- 资助金额:
$ 48.5万 - 项目类别:
Regulation of the neuroinflammatory response in autoimmune uveitis
自身免疫性葡萄膜炎神经炎症反应的调节
- 批准号:
10115860 - 财政年份:2021
- 资助金额:
$ 48.5万 - 项目类别:
Regulation of the neuroinflammatory response in autoimmune uveitis
自身免疫性葡萄膜炎神经炎症反应的调节
- 批准号:
10527371 - 财政年份:2021
- 资助金额:
$ 48.5万 - 项目类别:
Uncoupling caspase 8-mediated-apotosis from caspase 8-mediated-inflammation in glaucoma.
将青光眼中 caspase 8 介导的细胞凋亡与 caspase 8 介导的炎症解偶联。
- 批准号:
9919567 - 财政年份:2019
- 资助金额:
$ 48.5万 - 项目类别:
Regulation of vascular leakage in age related macular degeneration
年龄相关性黄斑变性中血管渗漏的调节
- 批准号:
8385057 - 财政年份:2012
- 资助金额:
$ 48.5万 - 项目类别:
Regulation of vascular leakage in age related macular degeneration
年龄相关性黄斑变性中血管渗漏的调节
- 批准号:
8534134 - 财政年份:2012
- 资助金额:
$ 48.5万 - 项目类别:
Neurotoxicity and neuroprotection in the DBA/2J spontaneous model of glaucoma
DBA/2J 自发性青光眼模型的神经毒性和神经保护
- 批准号:
8389866 - 财政年份:2011
- 资助金额:
$ 48.5万 - 项目类别:
相似海外基金
Mechanisms that underlie the life/death decisions in a cell that activated apoptotic caspases
细胞中激活凋亡半胱天冬酶的生/死决策的机制
- 批准号:
10607815 - 财政年份:2023
- 资助金额:
$ 48.5万 - 项目类别:
Nuclear and chromatin aberrations during non-apoptotic cell death in C. elegans and mammals
线虫和哺乳动物非凋亡细胞死亡过程中的核和染色质畸变
- 批准号:
10723868 - 财政年份:2023
- 资助金额:
$ 48.5万 - 项目类别:
Non-apoptotic functions of caspase-3 in neural development
Caspase-3在神经发育中的非凋亡功能
- 批准号:
10862033 - 财政年份:2023
- 资助金额:
$ 48.5万 - 项目类别:
Apoptotic Donor Leukocytes to Promote Kidney Transplant Tolerance
凋亡供体白细胞促进肾移植耐受
- 批准号:
10622209 - 财政年份:2023
- 资助金额:
$ 48.5万 - 项目类别:
Design of apoptotic cell mimetic anti-inflammatory polymers for the treatment of cytokine storm
用于治疗细胞因子风暴的模拟凋亡细胞抗炎聚合物的设计
- 批准号:
22H03963 - 财政年份:2022
- 资助金额:
$ 48.5万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Identifying the mechanisms behind non-apoptotic functions of mitochondrial matrix-localized MCL-1
确定线粒体基质定位的 MCL-1 非凋亡功能背后的机制
- 批准号:
10537709 - 财政年份:2022
- 资助金额:
$ 48.5万 - 项目类别:
Environmental Carcinogens Induce Minority MOMP to Initiate Carcinogenesis in Lung Cancer and Mesothelioma whileMaintaining Apoptotic Resistance via Mcl-1
环境致癌物诱导少数 MOMP 引发肺癌和间皮瘤的癌变,同时通过 Mcl-1 维持细胞凋亡抵抗
- 批准号:
10356565 - 财政年份:2022
- 资助金额:
$ 48.5万 - 项目类别:
Targeting apoptotic cells to enhance radiotherapy
靶向凋亡细胞以增强放射治疗
- 批准号:
10708827 - 财政年份:2022
- 资助金额:
$ 48.5万 - 项目类别:
Activation of non-apoptotic cell death by the DNA damage response
DNA 损伤反应激活非凋亡细胞死亡
- 批准号:
10388929 - 财政年份:2022
- 资助金额:
$ 48.5万 - 项目类别:
Role of natural immunity to self apoptotic exosomes in maintaining immune homeostasis
对自凋亡外泌体的自然免疫在维持免疫稳态中的作用
- 批准号:
RGPIN-2021-03004 - 财政年份:2022
- 资助金额:
$ 48.5万 - 项目类别:
Discovery Grants Program - Individual